Rat CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 7, 2006, Pages 423-431

  Walubo, Andrew ^a   Barr, S ^a   Abraham, A M ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Hepatotoxicity; Nevirapine; Rat CYP3A and CYP2B1 2

Indexed keywords

CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 3A; DEXAMETHASONE; KETOCONAZOLE; LIVER ENZYME; NEVIRAPINE; THIOTEPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HISTOPATHOLOGY; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANIMALS; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPARTATE AMINOTRANSFERASES; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; ENZYME INDUCTION; HEPATITIS, TOXIC; INTUBATION, GASTROINTESTINAL; KETOCONAZOLE; LIVER; LIVER FUNCTION TESTS; MALE; NEVIRAPINE; RATS; RATS, SPRAGUE-DAWLEY; STEROID HYDROXYLASES; THIOTEPA; TIME FACTORS;

EID: 33750023151     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2006.28.7.1003580     Document Type: Article

References (27)

1. Cheeseman, S.H., Hattox, S.E., McLaughlin, M.M. et al. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993, 37: 178-82.
2. Mirochnick, M., Clarke, D.F., Dorenbaum, A. Nevirapine: Pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet 2000, 39: 281-93.
3. Martínez, E., Blanco, J.L., Arnaiz, J.A. et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001, 15: 1261-8.
4. Riska, P., Lamson, M., MacGregor, T. et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999, 27: 895-901.
5. Park, B.K., Pirmohamed, M., Kitteringham, N.R. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995, 68: 385-424.
6. Gonzalez, F.J. Molecular genetics of the P-450 superfamily. Pharmacol Ther 1990, 45: 1-38.
7. Harleton, E., Webster, M., Bumpus, N.N., Kent, U.M., Rae, J.M., Hollenberg, P.F. Metabolism of N,N,N-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J Pharmacol Exp Ther 2004, 310: 1011-9.
8. Guengerich F.P. Characterisation of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 1989, 29: 241-64.
9. Wrighton, S.A., Schuetz, E.G., Watkins, P.B. et al. Demonstration in multiple specie of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome-P450 of the rat. Mol Pharmacol 1985, 28: 312-21.
10. Cui, X., Thomas, A., Han, Y. et al. Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: Correlation study with induction in vivo. J Pharmacol Toxicol Methods 2005, 52: 234-43.
11. Reisler, R., Liou, S., Sevoss, J. et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment, July 8-11, Buenos Aires 2001, Abst 43.
12. Boyle, B. Risk factors for antiretroviral hepatotoxicity clarified. HIV and AIDS News Stories, 2002. Available at http://www. hivandhepatitis.com.
13. Watanabe, M., Tateishi, T., Asoh, M. et al. Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. Life Sci 1998, 63: 1685-92.
14. EMEA. Scientific discussion. Submitted by Boehringer Ingelheim to the European Agency for the Evaluation of Medicinal Products (EMEA), 2000, 1-22. File no. CPMP/1096/97.
15. Zhang, Y., Hsieh, Y., Izumi, T., Lin, E.T., Benet, L.Z. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 1998, 287: 246-52.
16. Rzeski, W., Pruskil, S., Macke, A. et al. Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol 2004, 56: 351-60.
17. Pascussi, J.M., Gerbal-Chaloin, S., Fabre, J.M., Maurel, P., Vilarem, MJ. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000, 58: 1441-50.
18. Schuetz, E.G., Schmid, W., Schutz, G. et al. The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver. Drug Metab Dispos 2000, 28: 268-78.
19. Tredger, J.M., Stoll, S. Cytochrome P450-Their impact on drug treatment. Hosp Pract 2000, 9: 167-73.
20. Erickson, D.A., Mather, G., Trager, W.F., Levy, R.H., Keirns, J.J. Characterisation of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999, 27: 1488-95.
21. Code, E.L., Crespi, C.L., Penman, B.W., Gonzalez, F.J., Chang, T.K., Waxman, D.J. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997, 25: 985-93.
22. Schwartz, P.S., Waxman, D.J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 2001, 60: 1268-79.
23. Mori, Y., Iimura, K., Furukawa, F., Nishikawa, A., Takahashi, M., Konishi, Y. Effect of cigarette smoke on the mutagenic activation of various carcinogens in hamster. Mutat Res 1995, 346: 1-8.
24. Kishimoto, W., Takano, J., Senda, C., Ishiguro, N., Sakai, K., Igarashi, T. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 2000, 23: 1027-32.
25. Walubo, A., Smith, P., Folb, P.I. The role of oxygen free radicals in isoniazid-induced hepatotoxicity. Methods Find Exp Clin Pharmacol 1998, 20: 649-55.
26. Pampori, N.A., Shapiro, B.H. Gender differences in the responsiveness of the sex-dependent isoforms of hepatic P450 to the feminine plasma growth hormone profile. Endocrinology 1999, 140: 1245-54.
27. Michalets, E.L. Update: Clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998, 18: 84-112.